178 related articles for article (PubMed ID: 12566899)
21. [Chemotherapy of advanced bone and soft tissue sarcoma].
Yamawaki S; Isu K; Ubayama Y; Yamaguti H; Gotou M
Gan To Kagaku Ryoho; 1984 Sep; 11(9):1757-63. PubMed ID: 6541020
[TBL] [Abstract][Full Text] [Related]
22. Dose escalation study for defining the maximum tolerated dose of continuous oral trofosfamide in pretreated patients with metastatic lung cancer.
Al-Batran SE; Atmaca A; Bert F; Jäger D; Frisch C; Neumann A; Orth J; Knuth A; Jäger E
Onkologie; 2004 Dec; 27(6):534-8. PubMed ID: 15591711
[TBL] [Abstract][Full Text] [Related]
23. High-dose ifosfamide in the treatment of sarcomas of soft tissues and bone.
Demetri GD
Semin Oncol; 1996 Jun; 23(3 Suppl 6):22-6. PubMed ID: 8677444
[TBL] [Abstract][Full Text] [Related]
24. A two-arm phase II study of temozolomide in patients with advanced gastrointestinal stromal tumors and other soft tissue sarcomas.
Trent JC; Beach J; Burgess MA; Papadopolous N; Chen LL; Benjamin RS; Patel SR
Cancer; 2003 Dec; 98(12):2693-9. PubMed ID: 14669291
[TBL] [Abstract][Full Text] [Related]
25. Treatment of children with metastatic soft tissue sarcoma with oral maintenance compared to high dose chemotherapy: report of the HD CWS-96 trial.
Klingebiel T; Boos J; Beske F; Hallmen E; Int-Veen C; Dantonello T; Treuner J; Gadner H; Marky I; Kazanowska B; Koscielniak E
Pediatr Blood Cancer; 2008 Apr; 50(4):739-45. PubMed ID: 18286501
[TBL] [Abstract][Full Text] [Related]
26. Interruption versus continuation of trabectedin in patients with soft-tissue sarcoma (T-DIS): a randomised phase 2 trial.
Le Cesne A; Blay JY; Domont J; Tresch-Bruneel E; Chevreau C; Bertucci F; Delcambre C; Saada-Bouzid E; Piperno-Neumann S; Bay JO; Mir O; Ray-Coquard I; Ryckewaert T; Valentin T; Isambert N; Italiano A; Clisant S; Penel N
Lancet Oncol; 2015 Mar; 16(3):312-9. PubMed ID: 25680558
[TBL] [Abstract][Full Text] [Related]
27. Randomised phase II trial of trofosfamide vs. doxorubicin in elderly patients with untreated metastatic soft-tissue sarcoma.
Hartmann JT; Kopp HG; Gruenwald V; Piperno-Neumann S; Kunitz A; Hofheinz R; Mueller L; Geissler M; Horger M; Fix P; Chemnitz JM; Neise M; Wehler T; Zander I; Eckert R; Hann von Weyhern C; Bauer S; Mayer F;
Eur J Cancer; 2020 Jan; 124():152-160. PubMed ID: 31785463
[TBL] [Abstract][Full Text] [Related]
28. A role for maintenance therapy in managing sarcoma.
Ray-Coquard I; Le Cesne A
Cancer Treat Rev; 2012 Aug; 38(5):368-78. PubMed ID: 21843915
[TBL] [Abstract][Full Text] [Related]
29. ICE Regimen for Relapsed/Refractory Bone and Soft Tissue Sarcomas in Children.
Aydin B; Akyuz C; Varan A; Yalcin B; Kurucu N; Kutluk T
Rev Recent Clin Trials; 2018; 13(2):126-131. PubMed ID: 29366426
[TBL] [Abstract][Full Text] [Related]
30. Prognostic relevance of distant metastases versus locally advanced disease in soft tissue sarcomas: An EORTC-STBSG database study.
Verschoor AJ; Litière S; Marréaud S; Judson I; Toulmonde M; Wardelmann E; van der Graaf WT; Le Cesne A; Gronchi A; Gelderblom H
Eur J Cancer; 2018 May; 94():187-198. PubMed ID: 29574364
[TBL] [Abstract][Full Text] [Related]
31. Efficacy and safety of gemcitabine plus docetaxel in Japanese patients with unresectable or recurrent bone and soft tissue sarcoma: Results from a single-institutional analysis.
Takahashi M; Komine K; Imai H; Okada Y; Saijo K; Takahashi M; Shirota H; Ohori H; Takahashi S; Chiba N; Mori T; Shimodaira H; Ishioka C
PLoS One; 2017; 12(5):e0176972. PubMed ID: 28489919
[TBL] [Abstract][Full Text] [Related]
32. Cyclophosphamide, vincristine, adriamycin, and DTIC (CYVADIC) combination chemotherapy for the treatment of advanced sarcomas.
Yap BS; Baker LH; Sinkovics JG; Rivkin SE; Bottomley R; Thigpen T; Burgess MA; Benjamin RS; Bodey GP
Cancer Treat Rep; 1980 Jan; 64(1):93-8. PubMed ID: 7379060
[TBL] [Abstract][Full Text] [Related]
33. Optimizing the use of trabectedin for advanced soft tissue sarcoma in daily clinical practice.
Le Cesne A; Reichardt P
Future Oncol; 2015; 11(11 Suppl):3-14. PubMed ID: 26043310
[TBL] [Abstract][Full Text] [Related]
34. High-dose epirubicin is not an alternative to standard-dose doxorubicin in the treatment of advanced soft tissue sarcomas. A study of the EORTC soft tissue and bone sarcoma group.
Nielsen OS; Dombernowsky P; Mouridsen H; Crowther D; Verweij J; Buesa J; Steward W; Daugaard S; van Glabbeke M; Kirkpatrick A; Tursz T
Br J Cancer; 1998 Dec; 78(12):1634-9. PubMed ID: 9862576
[TBL] [Abstract][Full Text] [Related]
35. Recurrent low- to intermediate-grade chondrosarcoma of the thumb with lung metastases: an objective response to trofosfamide.
Debruyne PR; Dumez H; Demey W; Gillis L; Sciot R; Schöffski P
Onkologie; 2007 Apr; 30(4):201-4. PubMed ID: 17396043
[TBL] [Abstract][Full Text] [Related]
36. Phase II and pharmacokinetic study of ecteinascidin 743 in patients with progressive sarcomas of soft tissues refractory to chemotherapy.
Garcia-Carbonero R; Supko JG; Manola J; Seiden MV; Harmon D; Ryan DP; Quigley MT; Merriam P; Canniff J; Goss G; Matulonis U; Maki RG; Lopez T; Puchalski TA; Sancho MA; Gomez J; Guzman C; Jimeno J; Demetri GD
J Clin Oncol; 2004 Apr; 22(8):1480-90. PubMed ID: 15084621
[TBL] [Abstract][Full Text] [Related]
37. Oral metronomic cyclophosphamide with and without methotrexate as palliative treatment for patients with metastatic breast carcinoma.
Gebbia V; Boussen H; Valerio MR
Anticancer Res; 2012 Feb; 32(2):529-36. PubMed ID: 22287742
[TBL] [Abstract][Full Text] [Related]
38. Phase III trial of two investigational schedules of ifosfamide compared with standard-dose doxorubicin in advanced or metastatic soft tissue sarcoma: a European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group Study.
Lorigan P; Verweij J; Papai Z; Rodenhuis S; Le Cesne A; Leahy MG; Radford JA; Van Glabbeke MM; Kirkpatrick A; Hogendoorn PC; Blay JY;
J Clin Oncol; 2007 Jul; 25(21):3144-50. PubMed ID: 17634494
[TBL] [Abstract][Full Text] [Related]
39. Phase II trial of continuous oral trofosfamide in patients with advanced colorectal cancer refractory to 5-fluorouracil.
Strumberg D; Harstrick A; Klaassen U; Müller C; Eberhardt W; Korn MW; Wilke H; Seeber S
Anticancer Drugs; 1997 Mar; 8(3):293-5. PubMed ID: 9095336
[TBL] [Abstract][Full Text] [Related]
40. F-18 FDG PET and PET/CT evaluation of response to chemotherapy in bone and soft tissue sarcomas.
Iagaru A; Masamed R; Chawla SP; Menendez LR; Fedenko A; Conti PS
Clin Nucl Med; 2008 Jan; 33(1):8-13. PubMed ID: 18097248
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
